Anbio Biotechnology
NNNN · XNASCIK 1982708fmd_1K7TM2D8C72XMRER78GR84PRACManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2022 to Dec 31, 2025, 4 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total revenues | 24 | 7 | 8 | 9 |
| Cost of revenue | 11 | 3 | 2 | 1 |
| Gross profit | 13 | 3 | 6 | 8 |
| Realized investment gains (losses) | 0 | 0 | 0 | (0) |
| Research and development | 0 | 0 | 0 | 0 |
| Selling, general and administrative | 2 | 1 | 3 | 2 |
| Total operating expenses | 2 | 1 | 4 | 2 |
| Operating income | 10 | 2 | 2 | 6 |
| Interest expense | 0 | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (0) | 0 | 0 | 1 |
| Income before taxes | 10 | 2 | 2 | 6 |
| Income tax expense | – | 0 | 0 | 0 |
| Net income from continuing operations | – | 2 | 2 | 6 |
| Net income | 10 | 2 | 2 | 6 |